Skip to main content
Clinical Trials/NCT05858060
NCT05858060CompletedNot Applicable

Practice of Osmotherapy in Severe SubArachnoid Hemorrhage Patients: Multicenter Observational Study (OSMO-SAH Study)

Xuanwu Hospital, Beijing2 sites in 1 country124 target enrollmentStarted: July 10, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
124
Locations
2
Primary Endpoint
modified Rankin score

Study Overview

Brief Summary

The goal of this prospective multi-center observational study is to learn about the osmotic therapy in severe subarachnoid hemorrhage (SAH). The main question[s] it aims to answer are:

• whether the two osmotic therapy, 20% mannitol and 10% hypertonic saline(HTS), under the same osmotic equivalent, has similar influence on the outcome of SAH patients?

Participants will be given proper treatment according to local expert consensus, including the choice of osmotic medicine. Investigators just record and analyse the data, compare mannitol group and HTS group to see if the outcome of latter is not worse than the former.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • ①age ≥18; ②aneurysmal subarachnoid hemorrhage; ③Hunt-Hess 3-5 级

Exclusion Criteria

  • previous cranial decompression surgery, cerebrospinal fluid leakage or drainage,
  • bilateral pupils fixed or dilated,
  • hemodynamic instability,
  • hemoglobin < 8g / L,
  • serum osmolality > 320 mOsm / L,
  • ⑥ combined with severe organ dysfunction (cardiac, pulmonary, hepatic, renal and so on);
  • ⑦ serious electrolyte disorders (serum sodium concentration <125 mmol / L or >170 mmol / L), and difficult to correct within limited time;
  • ⑧ serious acid-base balance disorders, and difficult to correct within limited time;
  • ⑨ use of mannitol or HSS within previous six hours;
  • ⑩ being pregnant.

Outcomes

Primary Outcomes

modified Rankin score

Time Frame: 6 months

The Modified Rankin Score (mRS) is the most widely used outcome measure for brain injured patients, which ranges from 0-6. Score of 6 means that patient is dead.

modified Rankin score

Time Frame: 1 month after ictus

The Modified Rankin Score (mRS) is the most widely used outcome measure for brain injured patients, which ranges from 0-6. Score of 6 means that patient is dead.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Lidan Jiang

Principal Investigator

Xuanwu Hospital, Beijing

Study Sites (2)

Loading locations...

Similar Trials